The GLP-1 Lawsuit Explained, and the Muscle Loss Question It Leaves Out
A viral video circulating on X describes the latest happening with GLP-1 medications in stark terms: a "$2 billion lawsuit." The creator goes on to explain that patients have lost decades of muscle in a single year, and report stomach paralysis, blindness, teeth loss, and organ failure. The post has drawn substantial engagement.
Thousands of people are suing the makers of GLP-1 medications. The lawsuits have pushed a broader question into public conversation: what else is happening in the body during rapid weight loss that typical monitoring does not capture.
Muscle is the clearest example. Lean mass changes during GLP-1 treatment are well documented in clinical literature, they vary widely from person to person, and they might not show up on a routine annual blood panel until well after damage to the body occurs.
Why are people suing over GLP-1 medications?
Two federal multidistrict litigations are pending. The first suit covers gastrointestinal injuries including gastroparesis, ileus, and bowel obstruction. The other suit covers NAION vision loss claims involving Ozempic, Wegovy, Mounjaro, Trulicity, Zepbound, and other GLP-1 drugs.
The legal challenge in both is failure to warn. As of August 2026 there were 3,928 lawsuits pending in the gastrointestinal proceeding, and no case has reached trial. No settlement exists in either proceeding, and courts have made no findings of causation.
While muscle loss does not appear in either set of complaints, it still sits in the research literature, which is part of why it gets less attention than it warrants.
Here is what the published research shows.
How much muscle do people lose on GLP-1 medications?
Published trials report a wide range. Between roughly 15% and 60% of total weight lost can come from lean mass, depending on the medication, the dose, the population studied, and how body composition was measured.
A 2024 review in Diabetes, Obesity and Metabolism collected the figures across major trials. Some studies show lean mass reductions between 40% and 60% as a proportion of total weight lost. Others report approximately 15% or less. In the STEP-1 trial of semaglutide, lean mass fell by 6.92 kg, putting the fraction of weight lost from lean mass at 45.2%. In the SURMOUNT-1 trial of tirzepatide, lean mass fell by 5.67 kg, putting that fraction at 25.7%.
That spread is the finding. Two people on the same class of medication can end up with substantially different body composition outcomes, and the trial averages say very little about where any individual will land.
Does losing lean mass mean losing strength?
The research separates those two questions, and the answers differ.
The SEMALEAN study followed patients on semaglutide 2.4 mg over a year. Lean mass declined by 3 kg at month seven and stabilised after that. Handgrip strength improved by 4.5 kg at month 12. The prevalence of sarcopenic obesity fell from 49% at baseline to 33%.
Body composition ratios can also move in a favorable direction even while absolute lean mass falls. In the STEP 1 and SUSTAIN 8 trials, lean mass as a proportion of total body mass increased overall, pointing to an improvement in body composition.
Both things are true at once. Meaningful lean mass can leave, and overall composition and function can still improve. Which pattern a given person follows depends on factors that averages cannot predict.
Does standard bloodwork show muscle changes?
A routine annual panel is built to catch different things. It reports on kidney function, liver enzymes, lipids, blood sugar, and blood counts. Body composition and the protein markers associated with muscle turnover sit outside that scope.
The practical consequence is timing. Composition changes accumulate quietly over weeks and months, and the first clear signal often arrives through how someone feels rather than through a number on a lab report.
Dr. Heather Armstrong, Canada Research Chair, Associate Professor of Gastroenterology at the University of Alberta, and Dayhoff Health Clinical Advisor, has described the gap directly: by the time a standard panel reflects meaningful muscle change, a considerable amount of it has already happened.
How can someone track muscle loss while on a GLP-1?
A baseline is the starting point. Measuring biomarkers before beginning a GLP-1 give every later measurement something to be compared against.
The Dayhoff Health GLP-1 Map measures protein markers associated with lean mass, bone turnover, insulin sensitivity, and inflammation. Repeat measurement over the course of treatment shows the direction those markers are moving.
That information is for the conversation with a provider, who interprets your report alongside everything else in your clinical picture and directs any decision about the medication itself. Dayhoff Health adds a layer of measurement that runs alongside your annual physicals and routine bloodwork.
Frequently Asked Questions
How much muscle do people lose on GLP-1 medications? Published trials report a wide range, from roughly 15% to 60% of total weight lost coming from lean mass. STEP-1 reported 45.2%. SURMOUNT-1 reported 25.7%. Individual results vary considerably.
Does muscle loss on a GLP-1 mean losing strength? Not necessarily. The SEMALEAN study found handgrip strength improved by 4.5 kg over twelve months even as lean mass declined and then stabilised.
Are the GLP-1 lawsuits about muscle loss? No. The federal litigation covers gastrointestinal injuries in MDL 3094 and NAION vision loss in MDL 3163. Muscle loss appears in the research literature rather than the complaints.
Has anyone received a settlement? No. As of August 2026 there is no settlement in either proceeding, and no case has reached trial.
Will a standard annual physical show muscle changes? A routine panel is not designed to measure body composition or the protein markers associated with muscle turnover.
Should someone stop their medication because of muscle loss research? That decision belongs to the person and their provider. Measurement informs that conversation.
When is the best time to establish a baseline? Before a medication begins, so later measurements have a known starting point. People already on a GLP-1 can still establish a reference point and track from there.
The takeaway
The litigation will take years to resolve, and it addresses injuries separate from body composition. Muscle is the quieter question, and it applies to far more people than any lawsuit will.
Knowing where your markers started, and watching where they move, gives you something specific to bring to your provider.
References
- Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728
- SEMALEAN study. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673431/
- Semaglutide and GLP-1: Effects on lean body mass still unclear. Drug Discovery Trends. https://www.drugdiscoverytrends.com/glp-1-impact-lean-mass/
- Ozempic Lawsuit: August 2026 blindness and gastroparesis claims. Drugwatch. https://www.drugwatch.com/legal/ozempic-lawsuit/
- Ozempic Lawsuit: latest litigation news, August 2026. Miller & Zois. https://www.millerandzois.com/products-liability/drugs/ozempic-gallbladder-lawsuit/
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Dayhoff Health does not diagnose, treat, cure, or prevent any disease. Dayhoff Health programs are wellness monitoring tools and do not replace care from a licensed healthcare provider. Never start, stop, or change a medication without consulting your provider. Litigation described here reflects allegations that courts have not adjudicated; no finding of causation has been made against any manufacturer.